On August 19, iShares Biotechnology ETF rose 5.1% in regular trading, trading at $214.23/share, with turnover of $103 million.

The biotech sector is experiencing a confluence of positive catalysts. MNC acquisition activity has accelerated notably, with Argenx launching a $77-per-share tender offer to acquire Forte Biosciences, while Bank of America strategists have highlighted biotech as a compelling alternative to crowded AI trades, recommending investors rotate into the sector for uncorrelated alpha.

Additionally, Regeneron's Libtayo received Health Canada approval for adjuvant treatment of high-risk cutaneous squamous cell carcinoma, further boosting sentiment. AI-driven drug discovery orders continue to land, lifting upstream life sciences demand and improving overall sector fundamentals. OmniAb also unveiled a new partnership with Eli Lilly on ion-channel drug discovery, reinforcing the theme of robust deal-making activity across the space.

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)